NCT02070731已完成不适用
A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation
Keystone Heart15 个研究点 分布在 6 个国家目标入组 86 人开始时间: 2014年2月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 86
- 试验地点
- 15
- 主要终点
- In hospital procedural safety
研究概览
简要总结
A randomized evaluation of the TriGuard™ HDH embolic deflection device during transcatheter aortic valve implantation.
详细描述
The TriGuard HDH device is an aortic embolism deflection device intended to reduce the amount of embolic material that may enter the carotid, subclavian, and vertebral arteries during transcatheter heart valve implantation.
To assess the safety, efficacy, and performance of the TriGuard HDH embolic deflection device in patients undergoing transcatheter aortic valve implantation (TAVI), in comparison with patients undergoing unprotected TAVI.
Subjects with indications for TAVI and who meet study eligibility criteria will be randomized 1:1 to one of two treatment arms:
- Intervention - TAVI with the TriGuard HDH embolic deflection device
- Control - standard unprotected TAVI
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is a male or non-pregnant female ≥18 years of age
- •Patient meets indications for TAVI
- •The patient is willing to comply with protocol-specified follow-up evaluations
- •The patient, or legally authorized representative, has been informed of the nature of the study, agrees to its provisions and has provided written informed consent, approved by the appropriate Medical Ethics Committee (EC) or Institutional Review Board (IRB)
排除标准
- •Patients undergoing TAVI via the trans-axillary, trans-subclavian, or trans-aortic route
- •Patients undergoing TAVI via the transapical approach due to friable or mobile atherosclerotic plaque in the aortic arch
- •Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to index procedure per site standard test
- •Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours preceding the index procedure (according to definition) or AMI >72 hours preceding the index procedure, in whom creatine kinase and creatine kinase-Muscle Brain have not returned to within normal limits at the time of procedure.
- •Patients who are currently experiencing clinical symptoms consistent with new-onset AMI, such as nitrate-unresponsive prolonged chest pain
- •Patients with a history of bleeding diathesis or coagulopathy or patients in whom anti-platelet and/or anticoagulant therapy is contraindicated, or who will refuse transfusion
- •Patients with known other mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol, confound the data interpretation, or is associated with a life expectancy of less than one year
- •Patients with severe allergy to heparin or known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast sensitivity that cannot be adequately pre-medicated
- •Patients with a history of a stroke or transient ischemic attack (TIA) within the prior 6 months
- •Patients with an active peptic ulcer or history of upper gastrointestinal (GI) bleeding within the prior 6 months
- •Patients with renal failure (estimated Glomerular Filtration Rate [estimated Glomerular Filtration Rate] <30 mL/min, calculated from serum creatinine by the Cockcroft-Gault formula)
- •Patients with hepatic failure (Child-Pugh class C)
- •Patients with hypercoagulable states that cannot be corrected by additional periprocedural heparin
- •Patients presenting with cardiogenic shock or severe hypotension (systolic blood pressure <90 mm Hg) at the time of the index procedure
- •Patients with severe peripheral arterial disease that precludes delivery sheath vascular access
- •Patients with a heavily calcified or severely atheromatous aortic arch
- •Patients with an innominate artery ostium diameter <11 mm
- •Patients with a transverse aortic diameter >40 mm
- •Patients with anatomic irregularities of the aortic arch or innominate artery that could prevent positioning and stability of the device
- •Patients with contraindication to cerebral MRI
- •Patients who have a planned treatment with any other investigational device or procedure during the study period
- •Patients planned to undergo any other cardiac surgical or interventional procedure (e.g., concurrent coronary revascularization) during the TAVI procedure or within two (2) weeks prior to the TAVI procedure.
结局指标
主要结局
In hospital procedural safety
时间窗: Up to 7 days during post procedure hospitalization
In-hospital procedural safety, defined as the composite of the following Major Adverse Cardiovascular and Cerebrovascular Events (MACCE): * All-cause mortality * All stroke (disabling and non-disabling) * Life threatening (or disabling) bleeding * Acute kidney injury - Stage 2 or 3 (including renal replacement therapy) * Major vascular complications
次要结局
未报告次要终点
研究者
研究点 (15)
Loading locations...
相似试验
已完成
不适用
The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve ImplantationSymptomatic Aortic StenosisNCT02536196Keystone Heart478
已完成
1 期
A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic AneurysmsAbdominal Aortic AneurysmNCT00646048Boston Scientific Corporation43
招募中
不适用
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™Aortic Valve InsufficiencyAortic RegurgitationAortic InsufficiencyNCT06608823JenaValve Technology, Inc.1,016
招募中
不适用
Hydra Single-centre Experience - Copenhagen, DenmarkAortic Valve StenosisNCT06342635Sahajanand Medical Technologies Limited50
招募中
不适用
CTSN Embolic Protection TrialIschemic StrokeHeart Valve DiseaseAcute Kidney InjuryDeliriumCoronary Artery DiseaseNCT06027788Icahn School of Medicine at Mount Sinai842